Radiotherapy Dose to Lung Affects Overall Survival Among Patients With Esophageal Cancer

Share this content:
Researchers evaluated the outcomes of 453 patients with stage I to III esophageal cancer who received definitive or preoperative chemoradiation.
Researchers evaluated the outcomes of 453 patients with stage I to III esophageal cancer who received definitive or preoperative chemoradiation.
The following article features coverage from the 2018 Gastrointestinal Cancers Symposium. Click here to read more of Cancer Therapy Advisor's conference coverage.

A large chemoradiation dose to the lung is a significant independent predictor for survival among patients with esophageal cancer, according to an abstract being presented at the 2018 Gastrointestinal Cancers Symposium in San Francisco, California.1

For this study, researchers evaluated the outcomes of 453 patients with stage I to III esophageal cancer who received definitive or preoperative chemoradiation. Nearly 98% of patients received intensity modulated radiation therapy, and researchers reviewed the dose-volume histogram (DVH) metrics for the heart (max and mean dose, V5Gy, V10Gy, V20Gy, V30Gy, and V40Gy) and lung (mean dose, V5Gy and V20Gy). Other clinical factors, such as surgery, performance status, histology, and stage, were assessed.

Continue Reading Below

The mean follow-up was 28.4 months. Significant associations were observed between older age, not having undergone surgery, worse performance status, stage III disease, heart V40Gy, lung V5Gy, lung V20Gy, and decreased survival.

Further analysis with multivariate regression revealed, however, that while lung V20Gy (P = .0389), surgery (P = .008), and stage III disease (P < .0002) continued to be significant factors affecting survival, a large heart dose of V40Gy was not. Patients with V20Gy less than 20% had a median survival of 44.0 months compared with 24.0 months among patients with lung V20Gy 20% and greater.

The authors concluded that “esophageal cancer outcomes may be improved by minimizing lung dose, particularly the volume receiving 20Gy or more, and provides further rationale for pursuing new techniques to reduce lung dose, such as proton therapy.”

Read more of Cancer Therapy Advisor's coverage of the 2018 Gastrointestinal Cancers Symposium by visiting the conference page.

Reference

  1. Oh P, Zhang M, Brady P, et al. Impact of lung and heart dose on survival after radiotherapy for esophageal cancer. Oral presentation at: 2018 Gastrointestinal Cancers Symposium; January 18-20, 2018; San Francisco, CA.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs